Project Oncology®

Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer.Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest in cancer research with Project Oncology®.

182 episodes

10d ago latest

monthly cadence

English language

▶ Play latestRSS feed Website Science Medicine Health

https://reachmd.com/rss/itunes/70/?nocache

Episodes 182

R/R LBCL: A Practical Guide to CAR T Referral and Coordination
10d ago · 11:00
Guest: Loretta J. Nastoupil, MD Guest: Manali Kamdar, MD CAR T cell therapy has been established as a standard-of-care option in the second-line setting for appropriate relapsed/refractory patients with large B-cell lymphoma (LBCL).1 Some outcomes data suggest more favorable outcomes when CAR T is used in the second-line setting compared with subsequent lines of therapy.2,3 That’s why it’s important to not wait to refer and to consult with a CAR T specialist for all on-label patients—early evaluation gives patients the best opportunity to optimize outcomes.3,4 In this episode of Project Oncolo
Applying Clinical Trial Data in mCSPC Care
1mo ago · 12:45
Host: Steve Jackson, PharmD Guest: Jahan Aghalar, MD Guest: Ulka Vaishampayan, MD With more treatment options than ever for metastatic castration-sensitive prostate cancer (mCSPC), applying clinical trial data in everyday practice has become increasingly complex. Understanding how differences in trial design, patient populations, and clinical endpoints influence treatment decisions is essential for delivering personalized care. Join Dr. Steve Jackson as he speaks with Drs. Jahan Aghalar and Ulka Vaishampayan about practical approaches to interpreting the evidence and tailoring therapy to the p
Personalizing Long-Term mCSPC Treatment Decisions
1mo ago · 11:15
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Bilal Siddiqui, MD Long-term management of metastatic castration-sensitive prostate cancer (mCSPC) goes beyond selecting an effective therapy—it also requires careful consideration of tolerability, drug interactions, and treatment access. Balancing these factors can help clinicians personalize care while supporting adherence and quality of life over time. Joining Dr. Charles Turck to share practical strategies for navigating these decisions and tailoring treatment to each patient's unique needs is Dr. Bilal Siddiqui. He's an Assistant Professor i
Evidence-Based Treatment Decisions in Metastatic Triple-Negative Breast Cancer
2mo ago · 13:45
Host: Alexandria May, PharmD, BCPS Guest: Neil M. Iyengar, MD As first-line treatment options for metastatic triple-negative breast cancer continue to expand, emerging evidence and guideline updates are reshaping treatment selection. In this expert-led discussion, Dr. Alexandria May and Dr. Neil Iyengar review the growing role of biomarker-driven decision-making and examine how data from ASCENT-03, ASCENT-04, and TROPION-Breast02 are influencing preferred treatment approaches. Dr. Iyengar is the Director of the Cancer Survivorship Program and Co-Director of the Breast Medical Oncology Program
Side Effect Management in ALK+ Non-Small Cell Lung Cancer Care
2mo ago · 3:30
Guest: Urs Weber, MD For patients with ALK-positive non-small cell lung cancer, staying on therapy often means staying ahead of treatment-related toxicities. Join Dr. Urs Weber, Assistant Professor in the Division of Medical Oncology at the University of Colorado Anschutz Medical Campus, as he explores practical strategies for toxicity management, dose optimization, and shared decision-making to help support durable outcomes.
Beyond ALK Inhibition: Addressing Unmet Needs in Non-Small Cell Lung Cancer
2mo ago · 3:45
Guest: Urs Weber, MD Advances in targeted therapies have dramatically improved outcomes for patients with ALK-positive non-small cell lung cancer, but new resistance challenges continue to emerge. In this episode, Dr. Urs Weber discusses how cancers adapt to treatment, why off-target resistance and histologic transformation are becoming increasingly important, and where future research may help close critical gaps in care. Dr. Weber is an Assistant Professor in the Division of Medical Oncology at the University of Colorado Anschutz Medical Campus.
Building on Progress in ALK+ Non-Small Cell Lung Cancer Treatment
2mo ago · 2:15
Guest: Urs Weber, MD As outcomes improve for patients with ALK+ non-small cell lung cancer, attention is shifting toward therapies designed to push disease control even further. Tune in as Dr. Urs Weber examines promising agents in development and discusses the momentum driving the next phase of ALK-targeted treatment. Dr. Weber is an Assistant Professor in the Division of Medical Oncology at the University of Colorado Anschutz Medical Campus.
Post-BCMA Treatment Selection in R/R Multiple Myeloma
2mo ago · 14:15
Host: Steve Jackson, PharmD Guest: Nisha Joseph, MD This is a non-certified educational series produced and controlled by ReachMD. As BCMA-directed therapies move into earlier lines of care, more patients with relapsed and refractory (R/R) multiple myeloma are entering a treatment space with limited consensus on optimal sequencing strategies. In this conversation with Dr. Steve Jackson, Dr. Nisha Joseph explores how disease biology, immune exhaustion, prior treatment response, and patient-specific factors can guide therapy selection in this population. She's an Associate Professor in the Depar
Managing Immunotherapy Toxicities in Lung Cancer Patients
3mo ago · 9:30
Host: Jacob Sands, MD Guest: Aliyah Pabani, MD Lung cancer patients undergoing immunotherapy may be at risk for developing life-threatening toxicities. Find out how you can manage them with Dr. Jacob Sands and Dr. Aliyah Pabani, Clinical Assistant Professor in the Department of Medicine at the University of Calgary and Director of the Alberta Immunotherapy Database.
Optimizing Quality & Safety Systems to Reduce the Risk of Patient Harm
3mo ago · 14:00
Host: Jacob Sands, MD Guest: Joseph O. Jacobson, MD Over the past few decades, increasing attention has been placed on reducing the risk of patient harm within the healthcare system. Learn more about the risks that are specific to medical oncology and how current systems are addressing them with Dr. Jacob Sands and Dr. Joseph Jacobson, Senior Advisor for Quality and Patient Safety at Dana-Farber Cancer Institute.
Combating the Complexities of Cancer Care During Pregnancy
3mo ago · 4:30
Guest: Alison Wakoff Loren, MD, MSCE Cancer occurs in approximately 1 in every 1,000 pregnant patients and requires complex solutions from a multidisciplinary team. Learn more about the expanding management options for these patients with Dr. Alison Loren, Chief of the Division of Hematology and Oncology at the University of Pennsylvania Perelman School of Medicine.
Impact of Infertility & Elective Fertility Among Female Oncologists
3mo ago · 4:30
Guest: Emily MacDuffie, MD A recent survey conducted by physicians at Penn Medicine found that one-third of female oncologists reported experiencing infertility. Join Dr. Emily Macduffie, Radiation Oncology Resident Physician at Penn Medicine, as she speaks about potential solutions related to infertility for women in medicine based on her 2023 ASCO presentation.
Reducing the Rise of Uterine Cancer in the United States
3mo ago · 11:30
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Richard T. Penson, MD, MRCP Uterine cancer is the most common type of gynecologic malignancy in the United States, and disease mortality is on the rise. What do we need to know from recent studies to diagnose patients earlier? Take a deep dive with Dr. Charles Turck as he is joined by Dr. Richard Penson, Medical Oncologist specializing in Gynecologic Oncology at Massachusetts General Hospital in Boston.
Navigating NUT Carcinoma: Diagnosis and Treatment Strategies
3mo ago · 11:00
Host: Jacob Sands, MD Guest: Jia Luo, MD NUT carcinoma is a rare, aggressive form of cancer that’s highly resistant to therapy and has no defined standard treatment. Joining Dr. Jacob Sands to discuss the best diagnostic and treatment strategies for NUT carcinoma is Dr. Jia Luo, medical oncologist at Dana-Farber Cancer Institute and an Instructor of Medicine at Harvard Medical School in Boston.
Advancing Cancer Care: Key Considerations for Subcutaneous Immunotherapies
3mo ago · 6:15
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Hadfield, MD Subcutaneous cancer immunotherapies may offer a faster, more resource-efficient alternative to intravenous administration, improving patient convenience and accessibility while maintaining efficacy. However, careful monitoring for immunotherapy-related toxicities remains essential. Joining Dr. Charles Turck to discuss these key considerations for subcutaneous cancer immunotherapies is Dr. Matthew Hadfield, Assistant Professor of Medicine at Brown University/Alpert School of Medicine.
ReDiscover-2: Currently Enrolling Patients With PIK3CA-Mutated Advanced Breast Cancer
3mo ago · 16:45
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sarah Sammons, MD Despite advances in the treatment of HR-positive HER2-negative advanced breast cancer, patients with PIK3CA-mutated disease who progress after a CDK4/6 inhibitor still face limited effective and tolerable treatment options.1 This unmet need has fueled interest in zovegalisib (formerly RLY-2608), a next generation, pan-mutant-selective PI3Kα inhibitor designed to spare wild-type protein and potentially reduce class-related toxicities.2 Dr. Sarah Sammons joins Dr. Charles Turck to review key findings from the first-in-human ReDisc
Addressing Barriers to CAR T Referral in R/R LBCL
3mo ago · 12:45
Host: Steve Jackson, PharmD Guest: Matthew J. Matasar, MD Guest: Tycel Phillips, MD This is a non-certified educational series produced and controlled by ReachMD. Timely referral for CAR T-cell therapy remains a critical challenge for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL). From communication gaps between providers to logistical challenges and delays, barriers throughout the treatment pathway can limit timely access to care. Tune in to learn about evolving strategies that can help us streamline coordination and expand access to CAR T-cell therapy as Dr. Steve Jac
Urinary and Circulating Tumor DNA in Muscle-Invasive Bladder Cancer: NIAGARA Data
3mo ago · 13:30
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Petros Grivas, MD, PhD Could emerging biomarkers redefine how we assess response and recurrence risk in muscle-invasive bladder cancer? To find out, Dr. Charles Turck speaks with Dr. Petros Grivas about the key findings from the phase 3 NIAGARA trial. Together, they explore how perioperative durvalumab impacts circulating tumor DNA (ctDNA) clearance and clinical outcomes, including event-free and overall survival. Their conversation also highlights the prognostic value of ctDNA and the potential for urinary tumor DNA to more closely correlate wit
Beyond the Colonoscopy: New Screening Guidelines for Colorectal Cancer
4mo ago · 14:30
Host: Matt Birnholz, MD Several new screening tests have been developed to help doctors find colorectal cancer early when it's most treatable and can reduce the burden of this disease and the death toll nationwide. Host Dr. Matt Birnholz chats with Dr. John Kisiel, gastroenterologist and Assistant Professor of Medicine at Mayo Clinic College of Medicine, about new screening guidelines for detecting colorectal cancer.
Higher Risk, Lowered Age: New Colorectal Cancer Screening Guidelines
4mo ago · 12:30
Host: John Russell, MD Guest: Richard Wender, MD From oncologists to primary care, physicians are witnessing an alarming trend in younger patients: the rising risk of colorectal cancer. To investigate this growing threat, Dr. John Russell speaks with Dr. Rich Wender, Chief Cancer Control Officer at the American Cancer Society. Dr. Wender discusses the new colorectal cancer screening guidelines set forth and the methods behind the conclusion. While comparing past guidelines, Dr. Wender considers changes in our society and environment that may be contributing to increased cancer risks in younger
Combatting Challenges & Health Disparities in Colorectal Cancer Care
4mo ago · 13:00
Host: Jacob Sands, MD Guest: Edith Mitchell, MD, MACP, FCPP, FRCP Widespread health disparities have led to challenges in colorectal cancer screening. What's causing these disparities—and what are some ways we can overcome these obstacles? To dive into this topic, Dr. Jacob Sands is joined by Dr. Edith Mitchell from Thomas Jefferson University to discuss these disparities and how they may be impacting clinical outcomes.
ctDNA-Guided Adjuvant Atezolizumab in MIBC: IMvigor011 Insights
4mo ago · 9:00
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Guru P. Sonpavde, MD What if molecular relapse in muscle-invasive bladder cancer (MIBC) could be detected early enough to better inform treatment decisions? To find out, Dr. Charles Turck speaks with Dr. Guru Sonpavde to explore new IMvigor011 findings presented at the 2026 ASCO Genitourinary Cancers Symposium. Their discussion highlights how ctDNA monitoring identifies early recurrence risk, captures real-time immunotherapy activity, and positions ctDNA clearance as a powerful prognostic marker. Dr. Sonpavde is the Medical Director of Genitourin
ctDNA-Guided Bladder Preservation in Muscle-Invasive Bladder Cancer
4mo ago · 11:15
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Pooja Ghatalia, MD Emerging evidence is redefining bladder preservation strategies in muscle-invasive bladder cancer, with circulating tumor DNA (ctDNA) offering a novel approach to response-adapted care. Joining Dr. Charles Turck to review findings from the phase II RETAIN trials, which highlight how ctDNA clearance correlates with improved metastasis-free survival and informs risk stratification, is Dr. Pooja Ghatalia. She also examines the strengths and limitations of ctDNA, including its prognostic value for systemic recurrence and its inabil
How the First Metastatic Site Shapes Survival in Breast Cancer Relapse
7mo ago · 4:15
Presenter: Ryan Quigley Not all metastatic breast cancer is created equal. This AudioAbstract spotlights new data from a multicenter study in Japan that highlights how the first site of distant recurrence can significantly shape a patient’s prognosis. By isolating cases with single-organ metastasis, the study draws sharp contrasts in survival based on metastatic location, revealing that patients with brain or liver involvement fare far worse than those with bone or lung metastases. Tune in to better understand how site and even biology and presentation can guide care for patients with metastat
Advancing HER2-Targeted Therapy in GI Cancers
7mo ago · 5:30
Guest: John H. Strickler, MD The treatment landscape for HER2-positive gastroesophageal cancer is rapidly evolving, with zanidatamab emerging as a new option following years of limited progress beyond trastuzumab. Dr. John Strickler joins us to share insights on how recent FDA approvals and novel agents are transforming outcomes in this complex disease setting. Dr. Strickler is a Professor of Medicine in the Division of Medical Oncology at Duke University School of Medicine and Co-Leader for the Precision Cancer Medicine and Investigational Therapeutics Program at the Duke Cancer Institute.